How Do I Qualify for Ozempic for Weight Loss?

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

There is no weight-loss qualification for Ozempic, because Ozempic is not approved for weight loss. The Ozempic prescribing information lists three indications and all three are in type 2 diabetes: improving glycemic control as an adjunct to diet and exercise, reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with chronic kidney disease. The BMI thresholds people are usually thinking of when they ask this question belong to a different product — Wegovy, which contains the same molecule under a separate approval built on weight-management trials.

What the Ozempic Label Actually Requires

The gateway to Ozempic is a diagnosis of type 2 diabetes mellitus. Everything else in the label — the cardiovascular indication, the cardiorenal indication — sits on top of that diagnosis rather than beside it. Nothing in the labeling defines a body mass index threshold for eligibility, because body mass index is not part of how the product was studied or approved.

That matters practically. When a clinician evaluates someone for Ozempic, the questions are about glycemic control, HbA1c, existing cardiovascular disease, and kidney function. Weight change is measured and discussed, but it is not the criterion the approval rests on, and it is not what a payer adjudicates against.

The BMI Criteria You Are Thinking Of Belong to Wegovy

Wegovy injection is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. The weight-management trials that supported it enrolled adults with a BMI of 30 kg/m² or greater, or 27 to 29.9 kg/m² with at least one weight-related condition.

Wegovy's label carries two other doors as well: reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, and treating noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. Wegovy tablets exist too, at 1.5, 4, 9 and 25 mg, but they carry only the cardiovascular and weight-reduction indications — not the pediatric or MASH ones.

Off-Label Prescribing Is Legal, But It Is Not Qualification

A licensed clinician may prescribe an approved drug outside its labeled indication when they judge it clinically appropriate. That practice is lawful and long-standing across medicine. What it is not is a shortcut around eligibility, because there is no published eligibility standard for an off-label use — the determination rests entirely on the individual prescriber's judgment about that individual patient.

It also has downstream consequences. Coverage generally follows the labeled indication, so an off-label prescription for weight loss is unlikely to be reimbursed even when the drug itself sits on formulary. And it means the safety and efficacy data supporting the decision were generated in a different population than the one being treated.

What a Prescriber Screens For Regardless of Product

Every semaglutide label carries a boxed warning about the risk of thyroid C-cell tumors. In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; whether it does so in humans is unknown. Both Ozempic and Wegovy are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or any excipient.

Beyond the contraindications sit the warnings that shape a real conversation: acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or an insulin secretagogue, acute kidney injury from volume depletion, severe gastrointestinal reactions with a specific note that the drug is not recommended in severe gastroparesis, diabetic retinopathy complications in type 2 diabetes, increases in resting heart rate, and rare reports of pulmonary aspiration during general anesthesia or deep sedation. Pregnancy is a further consideration; the Wegovy label advises discontinuation at least two months before a planned pregnancy because of semaglutide's long half-life.

Where Compounded Semaglutide Fits

Compounded semaglutide is a distinct regulatory category, not a cheaper version of Ozempic. The FDA states plainly that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before they are marketed. There is no approved generic semaglutide, so no compounded preparation can accurately be described as a generic version of Ozempic.

A compounded preparation is made by a licensed pharmacy against a prescription written for a specific patient. That means the clinical screening described above still happens — the same contraindications, the same warnings, the same requirement for a prescriber who knows your history. What changes is the payment pathway, not the medical evaluation.

How to Ask the Question More Usefully

Instead of asking whether you qualify for Ozempic for weight loss, the more productive framing is: given my diagnoses, my history and my goals, which approved indication does my situation actually fall under, and which product is labeled for it? For some people the honest answer is a diabetes indication. For others it is a weight-management indication under a different brand. For others still, no approved indication applies and the conversation shifts to what a prescriber is willing to consider off-label and why.

That conversation belongs with a clinician who can see your labs, your medication list and your history. No online checklist can substitute for it, and any service that tells you that you qualify before a prescriber has reviewed your file is describing a marketing funnel rather than a medical assessment.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is there a BMI requirement for Ozempic?

No. The Ozempic prescribing information contains no BMI eligibility criterion, because Ozempic is indicated for type 2 diabetes rather than weight management. Its three labeled uses are glycemic control, reduction of major adverse cardiovascular events in adults with established cardiovascular disease, and reduction of the risk of sustained eGFR decline and end-stage kidney disease in chronic kidney disease. The BMI thresholds people associate with semaglutide come from Wegovy's weight-management labeling.

What are Wegovy's eligibility criteria for weight management?

Wegovy injection is indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. The supporting adult trials enrolled participants with a BMI of 30 kg/m² or greater, or 27 to 29.9 kg/m² with at least one weight-related condition such as hypertension or dyslipidemia.

Can a doctor prescribe Ozempic off-label for weight loss?

Licensed clinicians may prescribe approved medicines outside their labeled indications when they judge it clinically appropriate, and that is lawful. However, off-label use does not create an eligibility standard, does not change the FDA approval status, and does not obligate an insurer to pay. The decision rests entirely with the prescriber, who is weighing your diagnoses, your other medications and your risk factors against evidence generated in a different population.

Who should not take semaglutide at all?

Both the Ozempic and Wegovy labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a prior serious hypersensitivity reaction to semaglutide or any excipient in the product. The labels also carry warnings covering pancreatitis, gallbladder disease, hypoglycemia with insulin or secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, and diabetic retinopathy.

Is compounded semaglutide the same as Ozempic?

No. Compounded semaglutide is not an FDA-approved finished product, and the FDA states it does not review compounded drugs for safety, effectiveness or quality before marketing. It is prepared by a licensed pharmacy against a prescription for an individual patient. Because no approved generic semaglutide exists, a compounded preparation cannot accurately be described as a generic version of Ozempic or of any other approved brand.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.